Showing results (21-30 of 125) with videos related to
Sort By:
Pageof 13
Breast (Edinburgh, Scotland)|July 23, 2023
Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancerSantiago Terán, Manuel Alva, Pablo Tolosa, et al.Geburtshilfe Und Frauenheilkunde|February 12, 2024
Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of RecurrencePeter A Fasching, Hans Kreipe, Lucia Del Mastro, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 23, 2024
Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide surveyOlga Martínez-Sáez, Javier Cortés, Eva Ciruelos, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 27, 2010
SEOM clinical guidelines for the treatment of early breast cancerSonia del Barco Berrón, Eva Ciruelos Gil, Ignacio Tusquets Trías de Bes, et al.Oncoimmunology|April 28, 2022
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasisAlberto Carretero-González, Marta Hergueta-Redondo, Sara Sánchez-Redondo, et al.Journal of Cancer Research and Therapeutics|January 13, 2015
Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancerMiguel J Sotelo, Jose Angel García-Sáenz, Luis Manso, et al.Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|April 1, 2018
[Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]José Palacios Calvo, Joan Albanell, Federico Rojo, et al.Cancer Treatment Reviews|December 13, 2019
Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patientsJavier Cortés, Eva Ciruelos, José Pérez-García, et al.Surgical Oncology|August 30, 2022
Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancerSofía Aragón-Sánchez, Eva Ciruelos-Gil, Laura López-Marín, et al.Breast (Edinburgh, Scotland)|March 5, 2014
The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancerEva Ciruelos, Tomás Pascual, María Luisa Arroyo Vozmediano, et al.Pageof 13